Grupos Investigadores

Líneas de Investigación

  • Terapia génica enfermedades renales
  • Terapia génica enfermedades hereditarias neurodegenerativas
  • Terapia génica enfermedades hereditarias hepáticas

Palabras Clave

  • Terapia génica
  • Enfermedades raras
  • Adenovirus
  • AAV

Publicaciones Científicas desde 2018

  • Autores: Zabaleta, N.; Torella, Laura; Weber, N. D.; et al.
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.76 N° 3 2022 págs. 869 - 887
    Resumen
    The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine. The initiation of several clinical trials using these approaches to treat metabolic liver disorders as well as the recently reported remarkable results obtained by patients with transthyretin amyloidosis highlight the advances in this field and show the potential of these therapies to treat these diseases safely and efficaciously. These advances have been possible due, firstly, to significant improvements made in RNA chemistry that increase its stability and prevent activation of the innate immune response and, secondly, to the development of very efficient liver-targeted RNA delivery systems. In parallel, the breakout of CRISPR/CRISPR-associated 9-based technology in the gene editing field has marked a turning point in in vivo modification of the cellular genome with therapeutic purposes, which can be based on gene supplementation, correction, or silencing. In the coming years we are likely to witness the therapeutic potential of these two strategies both separately and in combination. In this review we summarize the preclinical data obtained in animal models treated with mRNA as a therapeutic agent and discuss the different gene editing strategies applied to the treatment of liver diseases, highlighting both their therapeutic efficacy as well as safety concerns.
  • Autores: Weber, N. D. (Autor de correspondencia); Martinez Garcia, Javier; González Aseguinolaza, Gloria
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN 0168-8278 Vol.76 N° 3 2022 págs. 749 - 751
  • Autores: Pacin-Ruiz, B.; Cortese, M. F. (Autor de correspondencia); Tabernero, D. (Autor de correspondencia); et al.
    Revista: VIRUSES-BASEL
    ISSN 1999-4915 Vol.14 N° 2 2022 págs. 215
    Resumen
    The hepatitis delta virus (HDV) genome has an autocatalytic region called the ribozyme, which is essential for viral replication. The aim of this study was to use next-generation sequencing (NGS) to analyze the ribozyme quasispecies (QS) in order to study its evolution and identify highly conserved regions potentially suitable for a gene-silencing strategy. HDV RNA was extracted from 2 longitudinal samples of chronic HDV patients and the ribozyme (nucleotide, nt 688-771) was analyzed using NGS. QS conservation, variability and genetic distance were analyzed. Mutations were identified by aligning sequences with their specific genotype consensus. The main relevant mutations were tested in vitro. The ribozyme was conserved overall, with a hyper-conserved region between nt 715-745. No difference in QS was observed over time. The most variable region was between nt 739-769. Thirteen mutations were observed, with three showing a higher frequency: T23C, T69C and C64 deletion. This last strongly reduced HDV replication by more than 1 log in vitro. HDV Ribozyme QS was generally highly conserved and was maintained during follow-up. The most conserved portion may be a valuable target for a gene-silencing strategy. The presence of the C64 deletion may strongly impair viral replication, as it is a potential mechanism of viral persistence.
  • Autores: Murillo Sauca, Oihana; Collantes Martínez, María; Gazquez López, Cristina; et al.
    Revista: MOLECULAR THERAPY. METHODS & CLINICAL DEVELOPMENT
    ISSN 2329-0501 Vol.9 N° 26 2022 págs. 98 - 106
    Resumen
    Wilson's disease (WD) is an inherited disorder of copper metabolism associated with mutations in ATP7B gene. We have shown that the administration of an adeno-associated vector (AAV) encoding a mini version of human ATP7B (VTX-801) provides long-term correction of copper metabolism in a murine WD model. In preparation of a future clinical trial, we have evaluated by positron emission tomography (PET) the value of 64Cu biodistribution, excretion pattern, and blood kinetics as pharmacodynamic biomarkers of VTX-801 effects. Six-week-old WD mice were injected intravenously with increasing doses of VTX-801 and 3 weeks or 3 months later with [64Cu]CuCl2. Untreated WD and wild-type (WT) mice were included as controls. Control WD mice showed increased hepatic 64Cu retention, reduced fecal excretion of the radiotracer, and altered 64Cu blood kinetics (BK) compared with WT mice. VTX-801 treatment in WD mice resulted in a significant reduction of hepatic 64Cu accumulation, the restoration of fecal 64Cu excretion, and the correction of 64Cu BK. This study showed that VTX-801 restores physiological copper metabolism in WD mice, confirming the mechanism of action of VTX-801, and demonstrated the translational potential of [64Cu]CuCl2-PET to explore VTX-801 pharmacodynamics in a minimally invasive and sensitive manner in WD patients.
  • Autores: Silva Pilipich, Noelia Romina; Smerdou Picazo, Cristian (Autor de correspondencia); Vanrell, L. (Autor de correspondencia)
    Revista: MICROORGANISMS
    ISSN 2076-2607 Vol.9 N° 9 2021 págs. 1956
    Resumen
    Nanobodies are camelid-derived single-domain antibodies that present some advantages versus conventional antibodies, such as a smaller size, and higher tissue penetrability, stability, and hydrophilicity. Although nanobodies can be delivered as proteins, in vivo expression from adeno-associated viral (AAV) vectors represents an attractive strategy. This is due to the fact that AAV vectors, that can provide long-term expression of recombinant genes, have shown an excellent safety profile, and can accommodate genes for one or several nanobodies. In fact, several studies showed that AAV vectors can provide sustained nanobody expression both locally or systemically in preclinical models of human diseases. Some of the pathologies addressed with this technology include cancer, neurological, cardiovascular, infectious, and genetic diseases. Depending on the indication, AAV-delivered nanobodies can be expressed extracellularly or inside cells. Intracellular nanobodies or "intrabodies" carry out their function by interacting with cell proteins involved in disease and have also been designed to help elucidate cellular mechanisms by interfering with normal cell processes. Finally, nanobodies can also be used to retarget AAV vectors, when tethered to viral capsid proteins. This review covers applications in which AAV vectors have been used to deliver nanobodies, with a focus on their therapeutic use.
  • Autores: Maestro Galilea, Sheila; Weber, N. D.; Zabaleta, N.; et al.
    Revista: JHEP REPORTS
    ISSN 2589-5559 Vol.3 N° 4 2021 págs. 100300
    Resumen
    Gene therapy is becoming an increasingly valuable tool to treat many genetic diseases with no or limited treatment options. This is the case for hundreds of monogenic metabolic disorders of hepatic origin, for which liver transplantation remains the only cure. Furthermore, the liver contains 10-15% of the body's total blood volume, making it ideal for use as a factory to secrete proteins into the circulation. In recent decades, an expanding toolbox has become available for liver-directed gene delivery. Although viral vectors have long been the preferred approach to target hepatocytes, an increasing number of non-viral vectors are emerging as highly efficient vehicles for the delivery of genetic material. Herein, we review advances in gene delivery vectors targeting the liver and more specifically hepatocytes, covering strategies based on gene addition and gene editing, as well as the exciting results obtained with the use of RNA as a therapeutic molecule. Moreover, we will briefly summarise some of the limitations of current liver-directed gene therapy approaches and potential ways of overcoming them.
  • Autores: Cartón García, Fernando; Saande, Cassondra Jeanette; Meraviglia-Crivelli, D.; et al.
    Revista: BIOMEDICINES
    ISSN 2227-9059 Vol.9 N° 3 2021 págs. 303
    Resumen
    The global burden of chronic kidney disease (CKD) is increasing every year and represents a great cost for public healthcare systems, as the majority of these diseases are progressive. Therefore, there is an urgent need to develop new therapies. Oligonucleotide-based drugs are emerging as novel and promising alternatives to traditional drugs. Their expansion corresponds with new knowledge regarding the molecular basis underlying CKD, and they are already showing encouraging preclinical results, with two candidates being evaluated in clinical trials. However, despite recent technological advances, efficient kidney delivery remains challenging, and the presence of off-targets and side-effects precludes development and translation to the clinic. In this review, we provide an overview of the various oligotherapeutic strategies used preclinically, emphasizing the most recent findings in the field, together with the different strategies employed to achieve proper kidney delivery. The use of different nanotechnological platforms, including nanocarriers, nanoparticles, viral vectors or aptamers, and their potential for the development of more specific and effective treatments is also outlined.
  • Autores: González Aseguinolaza, Gloria (Autor de correspondencia); Izeta, A.; Martín Molina, F.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.32 N° 23-24 2021 págs. 1425 - 1426
  • Autores: Rodríguez García, Estefanía; Zabaleta Lasarte, Nerea; Gil Fariña, Irene; et al.
    Revista: JOURNAL OF IMMUNOLOGY
    ISSN 0022-1767 Vol.206 N° 2 2021 págs. 376 - 385
    Resumen
    Several dinucleotide cyclases, including cyclic GMP-AMP synthase, and their involvement in STING-mediated immunity have been extensively studied. In this study, we tested five bacterial diguanylate cyclases from the Gram-negative bacterium Salmonella Enteritidis, identifying AdrA as the most potent inducer of a STING-mediated IFN response. AdrA wild-type (wt) or its inactive version AdrA mutant (mut) were delivered by an adenovirus (Ad) vector. Dendritic cells obtained from wt mice and infected in vitro with Ad vector containing AdrA wt, but not mut, had increased activation markers and produced large amounts of several immunostimulatory cytokines. For dendritic cells derived from STING-deficient mice, no activation was detected. The potential antiviral activity of AdrAwas addressed in hepatitis B virus (HBV)-transgenic and adenovirus-associated virus (AAV)-HBV mouse models. Viremia in serum of Ad AdrAwt-treatedmice was reduced significantly compared with that in Ad AdrA mut-injected mice. The viral load in the liver at sacrifice was in line with this finding. To further elucidate the molecular mechanism(s) by which AdrA confers its antiviral function, the response in mice deficient in STING or its downstream effector molecules was analyzed. wt and IFN-alpha R (IFNAR)(-/-) animals were additionally treated with anti- TNF-alpha (Enbrel). Interestingly, albeit less pronounced than in wt mice, in IFNAR(-/-) and Enbrel-treated wt mice, a reduction of serum viremia was achieved-an observation that was lost in anti-TNF-alpha-treated IFNAR(-/-) animals. No effect of AdrA wt was seen in STING- deficient animals. Thus, although STING is indispensable for the antiviral activity of AdrA, type I IFN and TNF-alpha are both required and act synergistically.
  • Autores: Pérez Iturralde, Andrea; Carte Abad, Beatriz; Aldabe Arregui, Rafael (Autor de correspondencia)
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.32 N° 19 - 20 2021 págs. 1242 - 1250
    Resumen
    The efficiency of recombinant adeno-associated virus (AAV) vectors transducing host cells is very low, limiting their therapeutic potential in patients. There are several cellular pathways interacting and interfering with the journey of the AAV from the cell surface to the nucleus, opening the possibility to enhance AAV transduction by modifying these interactions. In this study, we explored the results of AAV hepatic transduction when different mammalian target of rapamycin (mTOR) inhibitors, rapamycin, MLN0128, RapaLink-1, were used in preconditioned juvenile and adult mice. We confirmed rapamycin as an AAV hepatic transduction enhancer in juvenile and adult mice; however, RapaLink-1, a stronger mTOR inhibitor and a clear hepatic autophagy inducer, had no positive effect. Moreover, MLN0128 reduced AAV hepatic transduction. Therefore, our results show a complex interaction between the mTOR pathway and AAV-mediated hepatic transduction and indicate that mTOR inhibition is not a straightforward strategy for improving AAV transduction. More studies are necessary to elucidate the molecular mechanisms involved in the positive and negative effects of mTOR inhibitors on AAV transduction efficiency.</p>
  • Autores: Casales Zoco, Erkuden; Martisová, Eva; Villanueva, H.; et al.
    Revista: SCIENTIFIC REPORTS
    ISSN 2045-2322 Vol.11 N° 1 2021 págs. 21427
    Resumen
    A promising therapy for patients with B-cell lymphoma is based on vaccination with idiotype monoclonal antibodies (mAbs). Since idiotypes are different in each tumor, a personalized vaccine has to be produced for each patient. Expression of immunoglobulins with appropriate post-translational modifications for human use often requires the use of stable mammalian cells that can be scaled-up to reach the desired level of production. We have used a noncytopathic self-amplifying RNA vector derived from Semliki Forest virus (ncSFV) to generate BHK cell lines expressing murine follicular lymphoma-derived idiotype A20 mAb. ncSFV/BHK cell lines expressed approximately 2 mg/L/24 h of A20 mAb with proper quaternary structure and a glycosylation pattern similar to that of A20 mAb produced by hybridoma cells. A20 mAb purified from the supernatant of a ncSFV cell line, or from the hybridoma, was conjugated to keyhole limpet hemocyanin and used to immunize Balb/c mice by administration of four weekly doses of 25 mu g of mAb. Both idiotype mAbs were able to induce a similar antitumor protection and longer survival compared to non-immunized mice. These results indicate that the ncSFV RNA vector could represent a quick and efficient system to produce patient-specific idiotypes with potential application as lymphoma vaccines.
  • Autores: Kaiser, R. A.; Weber, N. D.; Trigueros-Motos, L.; et al.
    Revista: JOURNAL OF INHERITED METABOLIC DISEASE
    ISSN 0141-8955 Vol.44 N° 6 2021 págs. 1369 - 1381
    Resumen
    Phenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here we use the synthetic AAV vector Anc80 via systemic administration to deliver a functional copy of a codon-optimized human PAH gene, with or without an intron spacer, to the Pah(enu2) mouse model of PKU. Dose-dependent transduction of the liver and expression of PAH mRNA were present with both vectors, resulting in significant and durable reduction of circulating phenylalanine, reaching near control levels in males. Coat color of treated Pah(enu2) mice reflected an increase in pigmentation from brown to the black color of control animals, further indicating functional restoration of phenylalanine metabolism and its byproduct melanin. There were no adverse effects associated with administration of AAV up to 5 x 10(12) VG/kg, the highest dose tested. Only minor and/or transient variations in some liver enzymes were observed in some of the AAV-dosed animals which were not associated with pathology findings in the liver. Finally, there was no impact on cell turnover or apoptosis as evaluated by Ki-67 and TUNEL staining, further supporting the safety of this approach. This study demonstrates the therapeutic potential of AAV Anc80 to safely and durably cure PKU in a mouse model, supporting development for clinical consideration.
  • Autores: Nistal-Villán, E. (Autor de correspondencia); Argemí Ballbé, José María; de Jaime Soguero, A.; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.32 N° 7-8 2021 págs. 341 - 348
    Resumen
    Tight control of transgene expression is key to ensure the efficacy of a wide range of gene therapy interventions, in which the magnitude and duration of gene expression have to be adjusted to therapeutic needs, thereby limiting secondary effects. The development of upgraded strategies to link transgene expression to pathological stress episodes is an unmet need in gene therapy. Here, we propose an expression strategy that associates transgene expression to an intracellular stress coping mechanism, the unfolded protein response. Specifically, we harnessed the cis elements required to sustain the noncanonical splicing of X-box binding protein 1 (XBP1) messenger RNA (mRNA) in response to the dysfunction of the endoplasmic reticulum (ER), a situation commonly known as ER stress, to drive the expression of heterologous genes. Since ER stress features a wide variety of pathological conditions, including viral infections, cancer, or metabolic disorders, this new expression module stimulates the synthesis of therapeutic genes as a response to cellular damage, and ensures their expression only when necessary. Validation of this inducible expression system was performed in vitro and in vivo, and its potential to limit/inhibit viral infections has been shown in proof-of principle experiments.
  • Autores: Weber, N. D.; Salas Gómez, David; Odriozola Moncayola, Leticia; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.29 N° 4 2021 págs. 14 - 15
  • Autores: Bazo Ochoa, Andrea; Lantero, A.; Mauleón Mayora, Itsaso; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.29 N° 4 Supl. 1 2021 págs. 254 - 255
  • Autores: Palmeiro, E. B.; Ibáñez, M.; Hernández Sáez, Carlos; et al.
    Revista: ANNALS OF ONCOLOGY
    ISSN 0923-7534 Vol.32 N° Supl. 5 2021 págs. S368 - S368
  • Autores: Weber, N. D.; Odriozola Moncayola, Leticia; Bouquet, C.; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.29 N° 4 2021 págs. 245 - 245
  • Autores: Ballesteros Briones, M. C. ; Silva Pilipich, Noelia Romina; Herrador Cañete, Guillermo; et al.
    Revista: CURRENT OPINION IN VIROLOGY
    ISSN 1879-6257 Vol.44 2020 págs. 145 - 153
    Resumen
    DNA or mRNA vaccines have potential advantages over conventional vaccines since they are easier to manufacture and have higher safety profiles. In particular, self-amplifying RNA (saRNA) derived from alphavirus expression vectors has shown to be very efficient to induce humoral and cellular responses against many antigens in preclinical models, being superior to non-replicating mRNA and DNA. This is mainly due to the fact that saRNA can provide very high expression levels and simultaneously induces strong innate responses, potentiating immunity. saRNA can be administered as viral particles or DNA, but direct delivery as RNA represents a safer and more simple approach. Although saRNA can be delivered as naked RNA, in vivo transfection can be enhanced by electroporation or by complexing it with cationic lipids or polymers. Alphavirus saRNA could have broad application to vaccinate against human pathogens, including emerging ones like SARS-CoV-2, for which clinical trials have been recently initiated.
  • Autores: González Aseguinolaza, Gloria (Autor de correspondencia)
    Revista: NEW ENGLAND JOURNAL OF MEDICINE
    ISSN 0028-4793 Vol.382 N° 24 2020 págs. 2366 - 2367
    Resumen
    The porphyrias are a group of rare and ultra-rare devastating disorders of heme biosynthesis. The majority of these disorders are inherited, and patients present with disabling symptoms that have a profound effect on their quality of life. The subtypes of acute hepatic porphyria - including acute intermittent porphyria (the most common subtype), hereditary coproporphyria, variegate porphyria, and delta-aminolevulinic acid (ALA) dehydratase-deficiency porphyria - are characterized by the occurrence of severe neurovisceral attacks. The genetic deficit that causes acute hepatic porphyria reduces heme availability under conditions of increased heme demands, which leads to activation of the heme-synthesis pathway and up-regulation of . . .
  • Autores: Silva-Pilipich, N.; Martisová, Eva; Ballesteros-Briones, M. C.; et al.
    Revista: BIOMEDICINES
    ISSN 2227-9059 Vol.8 N° 12 2020 págs. 562
    Resumen
    Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer. However, it requires repetitive systemic administration of high mAbs doses, often leading to adverse effects. We generated a novel nanobody against PD-1 (Nb11) able to block PD-1/PD-L1 interaction for both mouse and human molecules. Nb11 was cloned into an adeno-associated virus (AAV) vector downstream of four different promoters (CMV, CAG, EF1 alpha, and SFFV) and its expression was analyzed in cells from rodent (BHK) and human origin (Huh-7). Nb11 was expressed at high levels in vitro reaching 2-20 micrograms/mL with all promoters, except SFFV, which showed lower levels. Nb11 in vivo expression was evaluated in C57BL/6 mice after intravenous administration of AAV8 vectors. Nb11 serum levels increased steadily along time, reaching 1-3 microgram/mL two months post-treatment with the vector having the CAG promoter (AAV-CAG-Nb11), without evidence of toxicity. To test the antitumor potential of this vector, mice that received AAV-CAG-Nb11, or saline as control, were challenged with colon adenocarcinoma cells (MC38). AAV-CAG-Nb11 treatment prevented tumor formation in 30% of mice, significantly increasing survival. These data suggest that continuous expression of immunomodulatory nanobodies from long-term expression vectors could have antitumor effects with low toxicity.
  • Autores: Mevel, M. (Autor de correspondencia); Bouzelha, M. ; Leray, A.; et al.
    Revista: CHEMICAL SCIENCE
    ISSN 2041-6520 Vol.11 N° 4 2020 págs. 1122 - 1131
    Resumen
    Gene delivery vectors based on adeno-associated virus (AAV) are highly promising due to several desirable features of this parent virus, including a lack of pathogenicity, efficient infection of dividing and non-dividing cells and sustained maintenance of the viral genome. However, the conclusion from clinical data using these vectors is that there is a need to develop new AAVs with a higher transduction efficiency and specificity for relevant target tissues. To overcome these limitations, we chemically modified the surface of the capsid of AAV vectors. These modifications were achieved by chemical coupling of a ligand by the formation of a thiourea functionality between the amino group of the capsid proteins and the reactive isothiocyanate motif incorporated into the ligand. This strategy does not require genetic engineering of the capsid sequence. The proof of concept was first evidenced using a fluorophore (FITC). Next, we coupled the N-acetylgalactosamine ligand onto the surface of the AAV capsid for asialoglycoprotein receptor-mediated hepatocyte-targeted delivery. Chemically-modified capsids also showed reduced interactions with neutralizing antibodies. Taken together, our findings reveal the possibility of creating a specific engineered platform for targeting AAVs via chemical coupling.
  • Autores: Anasagasti, A. ; Lara-Lopez, A.; Milla-Navarro, S. ; et al.
    Revista: PHARMACEUTICS
    ISSN 1999-4923 Vol.12 N° 10 2020 págs. 913
    Resumen
    Inherited retinal dystrophies (IRDs) are a group of rare retinal conditions, including retinitis pigmentosa (RP), caused by monogenic mutations in 1 out of more than 250 genes. Despite recent advancements in gene therapy, there is still a lack of an effective treatment for this group of retinal conditions. MicroRNAs (miRNAs) are a class of highly conserved small non-coding RNAs that inhibit gene expression. Control of miRNAs-mediated protein expression has been described as a widely used mechanism for post-transcriptional regulation in many physiological and pathological processes in different organs, including the retina. Our main purpose was to test the hypothesis that modulation of a group of miRNAs can protect photoreceptor cells from death in the rd10 mouse model of retinitis pigmentosa. For this, we incorporated modulators of three miRNAs in adeno-associated viruses (AAVs), which were administered through sub-retinal injections. The results obtained indicate that inhibition of the miR-6937-5p slows down the visual deterioration of rd10 mice, reflected by an increased electroretinogram (ERG) wave response under scotopic conditions and significant preservation of the outer nuclear layer thickness. This work contributes to broadening our knowledge on the molecular mechanisms underlying retinitis pigmentosa and supports the development of novel therapeutic approaches for RP based on miRNA modulation.
  • Autores: Vinueza Gavilanes, Rodrigo; Íñigo Marco, Ignacio; Larrea, L. ; et al.
    Revista: NEUROBIOLOGY OF DISEASE
    ISSN 0969-9961 Vol.137 2020 págs. 104781
    Resumen
    Alpha-synuclein (aSyn) protein levels are sufficient to drive Parkinson's disease (PD) and other synucleinopathies. Despite the biomedical/therapeutic potential of aSyn protein regulation, little is known about mechanisms that limit/control aSyn levels. Here, we investigate the role of a post-translational modification, N-terminal acetylation, in aSyn neurotoxicity. N-terminal acetylation occurs in all aSyn molecules and has been proposed to determine its lipid binding and aggregation capacities; however, its effect in aSyn stability/neurotoxicity has not been evaluated. We generated N-terminal mutants that alter or block physiological aSyn N-terminal acetylation in wild-type or pathological mutant E46K aSyn versions and confirmed N-terminal acetylation status by mass spectrometry. By optical pulse-labeling in living primary neurons we documented a reduced half-life and accumulation of aSyn N-terminal mutants. To analyze the effect of N-terminal acetylation mutants in neuronal toxicity we took advantage of a neuronal model where aSyn toxicity was scored by longitudinal survival analysis. Salient features of aSyn neurotoxicity were previously investigated with this approach. aSyn-dependent neuronal death was recapitulated either by higher aSyn protein levels in the case of WT aSyn, or by the combined effect of protein levels and enhanced neurotoxicity conveyed by the E46K mutation. aSyn N-terminal mutations decreased E46K aSyn-dependent neuronal death both by reducing protein levels and, importantly, by reducing the intrinsic E46K aSyn toxicity, being the D2P mutant the least toxic. Together, our results illustrate that the N-terminus determines, most likely through its acetylation, aSyn protein levels and toxicity, identifying this modification as a potential therapeutic target.
  • Autores: Simoes, I. T.; Aranda, F. (Autor de correspondencia); Casado-Llombart, S. ; et al.
    Revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER
    ISSN 2051-1426 Vol.8 N° 1 2020 págs. e000172
    Resumen
    Background CD6 is a lymphocyte surface co-receptor physically associated with the T-cell receptor (TCR)/CD3 complex at the center of the immunological synapse. There, CD6 assists in cell-to-cell contact stabilization and modulation of activation/differentiation events through interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), its main reported ligand. While accumulating evidence is attracting new interest on targeting CD6 for therapeutic purposes in autoimmune disorders, little is known on its potential in cancer. In an attempt to elucidate the in vivo relevance of blocking CD6-mediated interactions in health and disease, we explored the consequences of expressing high circulating levels of a soluble form CD6 (sCD6) as a decoy receptor. Methods High sCD6 serum levels were achieved by using transgenic C57BL/6 mice expressing human sCD6 under the control of lymphoid-specific transcriptional elements (shCD6LckE mu Tg) or wild type either transduced with hepatotropic adeno-associated virus coding for mouse sCD6 or undergoing repeated infusions of recombinant human sCD6 protein. Characterization of sCD6-induced changes was performed by ex vivo flow cytometry and functional analyses of mouse lymphoid organ cells. The in vivo relevance of those changes was explored by challenging mice with subcutaneous or metastatic tumors induced by syngeneic cancer cells of different lineage origins. Results Through a combination of in vitro and in vivo studies, we show that circulating sCD6 expression induces defective regulatory T cell (Treg) generation and function, decreased CD166/ALCAM-mediated tumor cell proliferation/migration and impaired galectin-induced T-cell apoptosis, supporting the fact that sCD6 modulates antitumor lymphocyte effector function and tumorigenesis. Accordingly, sCD6 expression in vivo resulted in delayed subcutaneous tumor growth and/or reduced metastasis on challenge of mice with syngeneic cancer cells. Conclusions Evidence is provided for the disruption of CD6 receptor-ligand interactions as a feasible immunomodulatory approach in cancer.
  • Autores: Zalba Oteiza, Sara; Contreras Sandoval, Ana Margarita; Martisová, Eva; et al.
    Revista: PHARMACEUTICS
    ISSN 1999-4923 Vol.12 N° 6 2020 págs. 595
    Resumen
    Immunotherapy has changed the paradigm of cancer treatments. In this way, several combinatorial strategies based on monoclonal antibodies (mAb) such as anti (a)-PD-1 or anti (a)-PD-L1 are often reported to yield promising clinical benefits. However, the pharmacokinetic (PK) behavior of these mAbs is a critical issue that requires selective analytical techniques. Indeed, few publications report data on a-PD1/a-PD-L1 exposure and its relationship with therapeutic or toxic effects. In this regard, preclinical assays allow the time profiles of antibody plasma concentrations to be characterized rapidly and easily, which may help to increase PK knowledge. In this study, we have developed and validated two in-house ELISAs to quantify a-PD-1 and a-PD-L1 in plasma collected from tumor-bearing mice. The linear range for the a-PD-1 assay was 2.5-125 ng/mL and 0.11-3.125 ng/mL for the a-PD-L1 assay, whereas the intra-and inter-day precision was lower than 20% for both analytes. The PK characterization revealed a significant decrease in drug exposure after administration of multiple doses. Plasma half-life for a-PD-1 was slightly shorter (22.3 h) than for a-PD-L1 (46.7 h). To our knowledge, this is the first reported preclinical ELISA for these immune checkpoint inhibitors, which is sufficiently robust to be used in different preclinical models. These methods can help to understand the PK behavior of these antibodies under different scenarios and the relationship with response, thus guiding the choice of optimal doses in clinical settings.
  • Autores: Lasa Ventura, Marta; Neri, L.; Carte Abad, Beatriz; et al.
    Revista: JOURNAL OF MOLECULAR BIOLOGY
    ISSN 0022-2836 Vol.432 N° 22 2020 págs. 5889 - 5901
    Resumen
    Protein lifespan is regulated by co-translational modification by several enzymes, including methionine aminopeptidases and N-alpha-aminoterminal acetyltransferases. The NatB enzymatic complex is an N-terminal acetyltransferase constituted by two subunits, NAA20 and NAA25, whose interaction is necessary to avoid NAA20 catalytic subunit degradation. We found that deletion of the first five amino acids of hNAA20 or fusion of a peptide to its amino terminal end abolishes its interaction with hNAA25. Substitution of the second residue of hNAA20 with amino acids with small, uncharged side-chains allows NatB enzymatic complex formation. However, replacement by residues with large or charged side-chains interferes with its hNAA25 interaction, limiting functional NatB complex formation. Comparison of NAA20 eukaryotic sequences showed that the residue following the initial methionine, an amino acid with a small uncharged side-chain, has been evolutionarily conserved. We have confirmed the relevance of second amino acid characteristics of NAA20 in NatB enzymatic complex formation in Drosophila melanogaster. Moreover, we have evidenced the significance of NAA20 second residue in Saccharomyces cerevisiae using different NAA20 versions to reconstitute NatB formation in a yNAA20-KO yeast strain. The requirement in humans and in fruit flies of an amino acid with a small uncharged side-chain following the initial methionine of NAA20 suggests that methionine aminopeptidase action may be necessary for the NAA20 and NAA25 interaction. We showed that inhibition of MetAP2 expression blocked hNatB enzymatic complex formation by retaining the initial methionine of NAA20. Therefore, NatB-mediated protein N-terminal acetylation is dependent on methionine aminopeptidase, providing a regulatory mechanism for protein N-terminal maturation. (C) 2020 Elsevier Ltd. All rights reserved.
  • Autores: López-Manzaneda, S.; Ojeda-Pérez, I.; Zabaleta Lasarte, Nerea; et al.
    Revista: MOLECULAR THERAPY. METHODS & CLINICAL DEVELOPMENT
    ISSN 2329-0501 Vol.19 2020 págs. 426 - 437
    Resumen
    The development of advanced gene and cell therapies for the treatment of genetic diseases requires reliable animal and cellular models to test their efficacy. Moreover, the availability of the target human primary cells of these therapies is reduced in many diseases. The development of endonucleases that can cut into specific sites of the cell genome, as well as the repair of the generated break by non-homologous end-joining, results in a variety of outcomes, insertions, deletions, and inversions that can induce the disruption of any specific gene. Among the many methods that have been developed for gene editing, CRISPR-Cas9 technology has become one of the most widely used endonuclease tools due to its easy design and its low cost. It has also been reported that the use of two guides, instead of just the one required, reduces the outcomes of non-homologous end joining mainly to the precise genomic sequences between the cutting sites of the guides used. We have explored this strategy to generate useful cellular and animal models. Different distances between the two guides have been tested (from 8 to 500 bp apart), and using the optimal range of 30-60 bp we have obtained a human primary cellular model of a genetic disease, pyruvate kinase deficiency, where the availability of the target cells is limited. We have also generated an in vivo model of glycolate oxidase (GO) deficiency, which is an enzyme involved in the glyoxylate metabolism following the same strategy. We demonstrate that the use of two-guide CRISPR-Cas9-induced non-homologous end joining is a feasible and useful tool for disease modeling, and it is most relevant to those diseases in which it is difficult to get the cells that will be genetically manipulated.
  • Autores: Lantero, A.; Mauleón Mayora, Itsaso; Neri, L.; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.28 N° 4 2020 págs. 121 - 121
  • Autores: Ros, I.; Salas Gómez, David; Rodríguez Parra, Estefanía Maite; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.28 N° 4 2020 págs. 181 - 182
  • Autores: Prieto Valtueña, Jesús María; González Aseguinolaza, Gloria (Autor de correspondencia)
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.70 N° 3 2019 págs. 1061 - 1063
  • Autores: Salas Gómez, David; Kwikkers, K. L.; Zabaleta Lasarte, Nerea; et al.
    Revista: BLOOD ADVANCES
    ISSN 2473-9529 Vol.3 N° 17 2019 págs. 2632 - 2641
    Resumen
    Adeno-associated virus (AAV)-based liver gene therapy has been shown to be clinically successful. However, the presence of circulating neutralizing antibodies (NABs) against AAV vector capsids remains a major challenge as it may prevent successful transduction of the target cells. Therefore, there is a need to develop strategies that would enable AAV-mediated gene delivery to patients with preexisting anti-AAV NABs. In the current study, the feasibility of using an immunoadsorption (IA) procedure for repeated, liver-targeted gene delivery in nonhuman primates was explored. The animals were administered IV with recombinant AAV5 (rAAV5) carrying the reporter gene human secreted embryonic alkaline phosphatase (hSEAP). Seven weeks after the first rAAV treatment, all of the animals were readministered with rAAV5 carrying the therapeutic hemophilia B gene human factor IX (hFIX). Half of the animals administered with rAAV5-hSEAP underwent IA prior to the second rAAV5 exposure. The transduction efficacies of rAAV5-hSEAP and rAAV5-hFIX were assessed by measuring the levels of hSEAP and hFIX proteins. Although no hFIX was detected after rAAV5-hFIX readministration without prior IA, all animals submitted to IA showed therapeutic levels of hFIX expression, and a threshold of anti-AAV5 NAB levels compatible with successful readministration was demonstrated. In summary, our data demonstrate that the use of a clinically applicable IA procedure enables successful readministration of an rAAV5-based gene transfer in a clinically relevant animal model. Finally, the analysis of anti-AAV NAB levels in human subjects submitted to IA confirmed the safety and efficacy of the procedure to reduce anti-AAV NABs. Furthermore, clinical translation was assessed using an immunoglobulin G assay as surrogate.
  • Autores: Godoy, C. ; Tabernero, D. (Autor de correspondencia); Sopena, S.; et al.
    Revista: WORLD JOURNAL OF GASTROENTEROLOGY
    ISSN 1007-9327 Vol.25 N° 13 2019 págs. 1566 - 1579
    Resumen
    BACKGROUND Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV) replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein (HBx) is essential for HBV replication, determination of HBV X gene (HBX) quasispecies complexity in HBV/HDV infection compared to HBV mono-infection may provide information on the interactions between these two viruses. AIM To compare HBV quasispecies complexity in the HBX 5' region between chronic hepatitis delta (CHD) and chronic HBV mono-infected patients. METHODS Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-negative chronic HBV infection (CI, previously termed inactive carriers), 8/24 (33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels. The HBX 5' region [nucleotides (nt) 1255-1611] was then PCR-amplified for subsequent next-generation sequencing (MiSeq, Illumina, United States). HBV quasispecies complexity in the region analyzed was evaluated using incidence-based indices (number of haplotypes and number of mutations), abundance-based indices (Hill numbers of order 1 and 2), and functional indices (mutation frequency and nucleotide diversity). We also evaluated the pattern of nucleotide changes to investigate which of them could be the cause of the quasispecies complexity. RESULTS CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL, interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) (P = n.s.) or CI (3.2 logIU/mL, IQR 2.3-3.5) (P < 0.01) patients. The incidence and abundance indices indicated that HBV quasispecies complexity was significantly greater in CI than CHB. A similar trend was observed in CHD patients, although only Hill numbers of order 2 showed statistically significant differences (CHB 2.81, IQR 1.11-4.57 vs CHD 8.87, 6.56-11.18, P = 0.038). There were no significant differences in the functional indices, but CI and CHD patients also showed a trend towards greater complexity than CHB. No differences were found for any HBV quasispecies complexity indices between CHD and CI patients. G-to-A and C-to-T nucleotide changes, characteristic of APOBEC3G, were higher in CHD and CI than in CHB in genotype A haplotypes, but not in genotype D. The proportion of nt G-to-A vs A-to-G changes and C-to-T vs T-to-C changes in genotype A and D haplotypes in CHD patients showed no significant differences. In CHB and CI the results of these comparisons were dependent on HBV genotype. CONCLUSION The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.
  • Autores: Murillo Sauca, Oihana; Moreno Luqui, Daniel; Gazquez López, Cristina; et al.
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.70 N° 1 2019 págs. 108 - 126
    Resumen
    Gene therapy with an adeno-associated vector (AAV) serotype 8 encoding the human ATPase copper-transporting beta polypeptide (ATP7B) complementary DNA (cDNA; AAV8¿ATP7B) is able to provide long-term copper metabolism correction in 6-week-old male Wilson disease (WD) mice. However, the size of the genome (5.2 kilobases [kb]) surpasses the optimal packaging capacity of the vector, which resulted in low-yield production; in addition, further analyses in WD female mice and in animals with a more advanced disease revealed reduced therapeutic efficacy, as compared to younger males. To improve efficacy of the treatment, an optimized shorter AAV vector was generated, in which four out of six metal¿binding domains (MBDs) were deleted from the ATP7B coding sequence, giving rise to the miniATP7B protein (delta57-486-ATP7B). In contrast to AAV8-ATP7B, AAV8-miniATP7B could be produced at high titers and was able to restore copper homeostasis in 6- and 12-week-old male and female WD mice. In addition, a recently developed synthetic AAV vector, AAVAnc80, carrying the miniATP7B gene was similarly effective at preventing liver damage, restoring copper homeostasis, and improving survival 1 year after treatment. Transduction of approximately 20% of hepatocytes was sufficient to normalize copper homeostasis, suggesting that corrected hepatocytes are acting as a sink to eliminate excess of copper.
  • Autores: Gulias, P.; Guerra-Varela, J. ; González Aparicio, Manuela; et al.
    Revista: GENES
    ISSN 2073-4425 Vol.10 N° 12 2019
    Resumen
    Viral vector use is wide-spread in the field of gene therapy, with new clinical trials starting every year for different human pathologies and a growing number of agents being approved by regulatory agencies. However, preclinical testing is long and expensive, especially during the early stages of development. Nowadays, the model organism par excellence is the mouse (Mus musculus), and there are few investigations in which alternative models are used. Here, we assess the possibility of using zebrafish (Danio rerio) as an in vivo model for adenoviral vectors. We describe how El/E3-deleted adenoviral vectors achieve efficient transduction when they are administered to zebrafish embryos via intracranial injection. In addition, helper-dependent (high-capacity) adenoviral vectors allow sustained transgene expression in this organism. Taking into account the wide repertoire of genetically modified zebrafish lines, the ethical aspects, and the affordability of this model, we conclude that zebrafish could be an efficient alternative for the early-stage preclinical evaluation of adenoviral vectors.
  • Autores: Weber, N. D. (Autor de correspondencia); Odriozola, L. ; Martinez Garcia, Javier; et al.
    Revista: NATURE COMMUNICATIONS
    ISSN 2041-1723 Vol.10 N° 1 2019 págs. 5694
    Resumen
    Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease caused by mutations in the ABCB4 gene, resulting in a reduction in biliary phosphatidylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we report results from treating two- or five-week-old Abcb4(-/-) mice with an AAV vector expressing human ABCB4, resulting in significant decreases of PFIC3 disease biomarkers. All male mice achieved a sustained therapeutic effect up through 12 weeks, but the effect was achieved in only 50% of females. However, two-week-old females receiving a second inoculation three weeks later maintained the therapeutic effect. Upon sacrifice, markers of PFIC3 disease such as, hepatosplenomegaly, biliary phosphatidylcholine and liver histology were significantly improved. Thus, AAV-mediated gene therapy successfully prevented PFIC3 symptoms in a clinically relevant mouse model, representing a step forward in improving potential therapy options for PFIC3 patients.
  • Autores: Weber, N. D.; Odriozola, L.; Martinez Garcia, Javier; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.27 N° 4 2019 págs. 203 - 203
  • Autores: Torella, Laura; Raimondi, Ivan; Vales Aranguren, África; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.30 N° 11 2019 págs. A2 - A2
  • Autores: Silva Pilipich, Noelia Romina; Martisová, Eva; Ballesteros-Briones, M. C.; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.30 N° 11 2019 págs. A57 - A57
  • Autores: Weber, N. D.; Odriozola, L.; Martinez Garcia, Javier; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN 0168-8278 Vol.70 N° 1 2019 págs. E590
  • Autores: Ramon, G. C.; Maestro Galilea, Sheila; Usai, C. ; et al.
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.70 2019 págs. 632A - 632A
  • Autores: Murillo Sauca, Oihana; Moreno Luqui, Daniel; Gazquez López, Cristina; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.30 N° 11 2019 págs. A151 - A152
  • Autores: Zabaleta Lasarte, Nerea; Torella, L.; Vales Aranguren, África; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.27 N° 4 2019 págs. 368 - 368
  • Autores: Rodríguez Parra, Estefanía Maite; Zabaleta Lasarte, Nerea; Gil-Farina, I.; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.30 N° 11 2019 págs. A219 - A220
  • Autores: Maestro Galilea, Sheila; Camps, G.; Usai, C.; et al.
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.70 2019 págs. 640A - 640A
  • Autores: Ganan, I. R.; Salas, D.; Rodriguez, E.; et al.
    Revista: HUMAN GENE THERAPY
    ISSN 1043-0342 Vol.30 N° 11 2019 págs. A115 - A115
  • Autores: Ballesteros-Briones, M. C.; Martisová, Eva; Casales Zoco, Erkuden; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.27 N° 4 2019 págs. 268 - 268
  • Autores: Moreno Luqui, Daniel; Murillo Sauca, Oihana; Gazquez López, Cristina; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN 0168-8278 Vol.68 N° 5 2018 págs. 1088 - 1090
  • Autores: Suarez-Amaran, L.; Usai, C.; Di Scala, M.; et al.
    Revista: JOURNAL OF HEPATOLOGY
    ISSN 1600-0641 Vol.69 N° 1 2018 págs. 262 - 264
  • Autores: Torralba, D.; Baixauli, F. ; Villarroya-Beltri, C.; et al.
    Revista: NATURE COMMUNICATIONS
    ISSN 2041-1723 Vol.9 2018
    Resumen
    Interaction of T cell with antigen-bearing dendritic cells (DC) results in T cell activation, but whether this interaction has physiological consequences on DC function is largely unexplored. Here we show that when antigen-bearing DCs contact T cells, DCs initiate antipathogenic programs. Signals of this interaction are transmitted from the T cell to the DC, through extracellular vesicles (EV) that contain genomic and mitochondrial DNA, to induce antiviral responses via the cGAS/STING cytosolic DNA-sensing pathway and expression of IRF3-dependent interferon regulated genes. Moreover, EV-treated DCs are more resistant to subsequent viral infections. In summary, our results show that T cells prime DCs through the transfer of exosomal DNA, supporting a specific role for antigen-dependent contacts in conferring protection to DCs against pathogen infection. The reciprocal communication between innate and adaptive immune cells thus allow efficacious responses to unknown threats.
  • Autores: Rodríguez-García, E. ; Olague Micheltorena, María Cristina; Ríus-Rocabert, S. ; et al.
    Revista: IMMUNOHORIZONS
    ISSN 2573-7732 Vol.2 N° 11 2018 págs. 363 - 376
    Resumen
    The innate immune system provides a primary line of defense against pathogens. Stimulator of IFN genes (STING), encoded by the TMEM173 gene, is a critical protein involved in IFN-ß induction in response to infection by different pathogens. In this study, we describe the expression of three different alternative-spliced human (h) TMEM173 mRNAs producing STING truncated isoforms 1, 2, and 3 in addition to the full-length wild-type (wt) hSTING. All of the truncated isoforms lack exon 7 and share the N-terminal transmembrane region with wt hSTING. Overexpression of the three STING truncated isoforms failed to induce IFN-ß, and they acted as selective pathway inhibitors of wt hSTING even in combination with upstream inducer cyclic-di-GMP-AMP synthase. Truncated isoforms alter the stability of wt hSTING, reducing protein t1/2 to some extent by the induction of proteasome-dependent degradation. Knocking down expression of truncated isoforms increased production of IFN-ß by THP1 monocytes in response to intracellular cytosolic DNA or HSV-1 infection. At early stages of infection, viruses like HSV-1 or vesicular stomatitis virus reduced the ratio of full-length wt hSTING/truncated STING isoforms, suggesting the skewing of alternative splicing of STING toward truncated forms as a tactic to evade antiviral responses. Finally, in silico analysis revealed that the human intron¿exon gene architecture of TMEM173 (splice sites included) is preserved in other mammal species, predominantly primates, stressing the relevance of alternative splicing in regulating STING antiviral biology.
  • Autores: Murillo Sauca, Oihana; Moreno Luqui, Daniel; Gazquez López, Cristina; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN 0168-8278 Vol.68 N° Supl. 1 2018 págs. S83 - S83
  • Autores: Vinueza Gavilanes, Rodrigo; Adin Marcos, Íñigo; Larrea Urcola, Luis María; et al.
    Revista: FEBS OPEN BIO
    ISSN 2211-5463 Vol.8 N° Supl. 1 2018 págs. 412 - 412
  • Autores: González Aseguinolaza, Gloria; Murillo Sauca, Oihana; Moreno Luqui, Daniel; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.26 N° 5 2018 págs. 388 - 388
  • Autores: Neri, L. ; Dominguez, V.; Elurbide Tardio, Jasmin; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN 0168-8278 Vol.68 N° Supl. 1 2018 págs. S54 - S54
  • Autores: Maestro, S.; Cortese, M. F.; Gonzalez, C. ; et al.
    Revista: HEPATOLOGY
    ISSN 0270-9139 Vol.68 N° Supl. 1 2018 págs. 239A - 240A
  • Autores: González Aseguinolaza, Gloria; Murillo Sauca, Oihana; Moreno Luqui, Daniel; et al.
    Revista: MOLECULAR THERAPY
    ISSN 1525-0016 Vol.26 N° 5 2018 págs. 249 - 250

Proyectos desde 2018

  • Título: Generación de vectores de terapia génica quiméricos para tratar la poliquistosis renal autosómica dominante tipo II
    Código de expediente: 0011-1408-2020-000028
    Investigador principal: SERGIO MILAGROS SOLCHAGA.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: FIMA 2020 -GN DOCTORANDOS INDUSTRIALES 2020- 2021
    Fecha de inicio: 29-09-2020
    Fecha fin: 28-09-2023
    Importe concedido: 78.897,12 €
    Fondos FEDER: NO
  • Título: Gene therapy of colorectal cancer using a self-replicating RNA vector expressing inhibitors of tumor cell adhesion in combination with immunostimulatory antibodies
    Código de expediente: 0011-0537-2019-000006
    Investigador principal: GUILLERMO HERRADOR CAÑETE.
    Financiador: GOBIERNO DE NAVARRA / DPTO. EDUCACIÓN CULTURA Y TURISMO
    Convocatoria: FIMA GNE 2019 BECAS PREDOCTORALES
    Fecha de inicio: 01-06-2020
    Fecha fin: 15-10-2022
    Importe concedido: 68.715,96 €
    Fondos FEDER: NO
  • Título: Creación de una plataforma para el desarrollo de vectores de terápia génica con tropismo renal.(Drones Génicos)
    Código de expediente: 0011-1411-2019-000074
    Investigador principal: RAFAEL ALDABE ARREGUI.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: FIMA 2019 GN PROYECTOS ESTRATEGICOS DE I+D 2019-2021
    Fecha de inicio: 01-04-2019
    Fecha fin: 30-11-2021
    Importe concedido: 631.682,12 €
    Fondos FEDER: NO
  • Título: Análisis de la interación del virus de la hepatitis delta (HDV) con el hospedador y con el virus de la hepatitis B (HBV) (INTERDELTA
    Código de expediente: RTI2018-101936-B-I00
    Investigador principal: GLORIA GONZALEZ ASEGUINOLAZA.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2018 - PROYECTOS DE I+D RETOS INVESTIGACION
    Fecha de inicio: 01-01-2019
    Fecha fin: 30-09-2022
    Importe concedido: 338.800,00 €
    Fondos FEDER: SI
  • Título: RNA autorreplicativo armado con nanobodies inmunoestimuladores para terapia del cáncer colorectal
    Código de expediente: 64/2018
    Investigador principal: CRISTIAN SMERDOU PICAZO.
    Financiador: GOBIERNO DE NAVARRA. DEPARTAMENTO DE SALUD
    Convocatoria: 2018 PROYECTOS DE I+D EN SALUD
    Fecha de inicio: 31-12-2018
    Fecha fin: 30-12-2021
    Importe concedido: 78.775,00 €
    Fondos FEDER: SI
  • Título: Terapia génica con glucocerebrosidasa para el tratamiento de la enfermedad de Parkinson.
    Código de expediente: 0011-1383-2019-000006
    Investigador principal: JOSE LUIS LANCIEGO PEREZ.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2019 - GN INDUSTRIA PROYECTOS CENTROS TECNOLOGICOS Y ORGANISMOS DE INVESTIGACION
    Fecha de inicio: 01-12-2018
    Fecha fin: 30-11-2019
    Importe concedido: 132.648,00 €
    Fondos FEDER: NO
  • Título: Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales
    Código de expediente: RTC-2017-6600-1
    Investigador principal: RAFAEL ALDABE ARREGUI.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2017 - PROYECTOS RETOS-COLABORACION
    Fecha de inicio: 01-04-2018
    Fecha fin: 30-04-2022
    Importe concedido: 150.913,59 €
    Fondos FEDER: SI
  • Título: Selección y optimización de nuevas moléculas antitumorales. Validación de la acetilación aminoterminal de proteínas como diana terapéutica antitumoral.
    Código de expediente: 0011-1383-2018-000011
    Investigador principal: RAFAEL ALDABE ARREGUI.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2018 - GN INDUSTRIA PROYECTOS CENTROS TECNOLOGICOS Y ORGANISMOS DE INVESTIGACION
    Fecha de inicio: 01-02-2018
    Fecha fin: 30-11-2018
    Importe concedido: 175.851,50 €
    Fondos FEDER: NO
  • Título: CREACION DE UNA PLATAFORMA EUROPEA INNOVADORA DE TERAPIA GENICA PARA ENFERMEDADES HEREDITARIAS POCO FRECUENTES.
    Código de expediente: EUIN2017-89279
    Investigador principal: GLORIA GONZALEZ ASEGUINOLAZA.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2017 MINECO Europa Investigación
    Fecha de inicio: 01-10-2017
    Fecha fin: 30-09-2019
    Importe concedido: 20.700,00 €
    Fondos FEDER: SI
  • Título: PREPARACION DE LA PROPUESTA ITN-NMATTERS
    Código de expediente: EUIN2017-89194
    Investigador principal: RAFAEL ALDABE ARREGUI.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2017 MINECO Europa Investigación
    Fecha de inicio: 01-07-2017
    Fecha fin: 31-12-2018
    Importe concedido: 18.130,00 €
    Fondos FEDER: SI
  • Título: Desarrollo y caracterización de un modelo de infeccíón crónica por el virus de la Hepatitis Delta en ratón y desarrollo de nuevos tratamientos
    Código de expediente: SAF2015-70028-R
    Investigador principal: GLORIA GONZALEZ ASEGUINOLAZA.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2015 - PROYECTOS DE I+D RETOS
    Fecha de inicio: 01-01-2016
    Fecha fin: 31-12-2018
    Importe concedido: 210.240,00 €
    Fondos FEDER: SI
  • Título: Curing Dravet Syndrome by Gene Therapy
    Código de expediente: AC17/00029
    Investigador principal: ROCIO SANCHEZ-CARPINTERO ABAD
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: E-RARE
    Fecha de inicio: 01-01-2018
    Fecha fin: 31-05-2021
    Importe concedido: 59.290,00 €
    Fondos FEDER: SI
  • Título: Optimización de vectores de terapia génica para el tratamiento del síndrome de Dravet
    Investigador principal: RUBEN HERNANDEZ ALCOCEBA
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: FIMA 2020 -GN DOCTORANDOS INDUSTRIALES 2020- 2021
    Fecha de inicio: 24-09-2020
    Fecha fin: 30-09-2021
    Importe concedido: 14.000,00 €
  • Título: Desarrollo de nuevas estrategias de inmunoterapia para el tratamiento del cáncer colorectal usando vectores basados en RNA autorreplicativo
    Investigador principal: CRISTIAN SMERDOU PICAZO
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2017 - PROYECTOS DE I+D EN SALUD
    Fecha de inicio: 01-01-2018
    Fecha fin: 31-12-2021
    Importe concedido: 141.570,00 €
  • Título: Terapia Génica para el Síndrome de Dravet
    Investigador principal: MIGUEL VALENCIA USTARROZ
    Financiador: FUNDACION INOCENTE INOCENTE
    Convocatoria: FUNDACION INOCENTE INOCENTE 2017
    Fecha de inicio: 19-10-2017
    Fecha fin: 31-01-2019
    Importe concedido: 29.755,00 €